Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabozantinib in advanced hepatocellular carcinoma (ACTION)
NCT04316182Phase 2Completed
- Sponsor
- Fundació Clínic per a la Recerca Biomèdica
- Start
- Jul 2020
- Primary completion
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cabozantinib in hepatocellular carcinoma (HCC), sponsored by Fundació Clínic per a la Recerca Biomèdica. Primary endpoints: Rate of Adverse Events >= Grade 3 Excluding Palmar-plantar Erythrodysesthesia up to 18 months, Rate of Adverse Events up to 18 months and 3 more. Started Jul 2020; status: completed.
02
Drugs
cabozantinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT04316182.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04316182.